Splash Beverage Acquires Global Rights to CannEpil Epilepsy Therapy
Beverage maker pivots to pharma with exclusive licensing deal for cannabinoid treatment with European market presence and U.S. regulatory pathway.
Splash Beverage Group has secured exclusive global rights to CannEpil, a cannabinoid-based therapeutic for drug-resistant epilepsy, through a licensing agreement with Argent BioPharma. The transaction positions the beverage company in the pharmaceutical space with a candidate that has already achieved patient access in Europe and established engagement with U.S. regulatory authorities.
CannEpil represents a departure from Splash Beverage's core business as a beverage producer. The asset comes with existing commercial traction outside the United States, where it has reached patients, and a defined development pathway with the FDA. The acquisition reflects a broader corporate strategy to diversify revenue streams beyond traditional beverage categories.
The deal grants Splash Beverage the ability to develop and commercialize CannEpil across all territories globally. Drug-resistant epilepsy, which affects patients who do not respond to standard antiepileptic medications, represents a targeted therapeutic area with defined treatment protocols and patient registries that facilitate clinical development and market access.
Splash Beverage's move into pharmaceutical licensing suggests the company views cannabinoid therapeutics as an extension of its existing portfolio rather than a complete business pivot. The structure of the deal—acquiring rights to a late-stage asset with regulatory precedent rather than developing from early research—reduces technical risk and accelerates potential revenue contribution.
The company's engagement with the FDA on CannEpil indicates the pathway to U.S. approval is already in motion, a significant advantage given the extended timelines typical for novel therapeutics in this category. European patient access provides additional validation of the compound's clinical profile and manufacturing feasibility.
With this transaction, Splash Beverage enters a different competitive landscape where pharmaceutical expertise, regulatory relationships, and clinical data carry greater weight than brand marketing or distribution networks. Success will depend on the company's ability to navigate drug development protocols and maintain momentum through clinical trials required for U.S. market authorization.